Treatment of Metastatic Cancer in Terminally Diagnosed NCT05491928

Clinical Trial Details — Status: Available

Administrative data
NCT number	NCT05491928
Other study ID #	MBI-23-01
Secondary ID
Status	Available
Phase
First received
Last updated

Study information
Verified date	August 2022
Source	Matrix Biomed, Inc.
Contact	Benji Crane
Phone	6264376506
Email	bjcrane[@]matrixbiomed.com
Is FDA regulated	No
Health authority
Study type	Expanded Access

Clinical Trial Summary

The objective is to provide terminally diagnosed patients with a last line of treatment while improving overall quality of life. Tempol can be added to any chemotherapy regimen to potentially reduce side effects and overcome chemoresistance.

Description:

The objective is to provide terminally diagnosed patients assigned to palliative care and palliative chemotherapy a last line treatment with Tempol. In vivo studies have shown Tempol to work synergistically with a number of chemotherapy agents increasing treatment response and reducing chemoresistance. Additionally, Tempol has been shown to provide protection to non-cancerous cells allowing for increased chemotherapy dosing by reducing side effects. Tempol inhibits HIF-1/VEGF among others in cancerous cells while upregulating GSH/NrF2 among others in non-cancerous cells.

Recruitment information / eligibility
Status	Available
Enrollment	0
Est. completion date
Est. primary completion date
Accepts healthy volunteers
Gender	All
Age group	N/A and older
Eligibility	Inclusion Criteria: - metastatic terminally diagnosed cancer Exclusion Criteria: -

Study Design

Related Conditions & MeSH terms

Intervention

Drug:
• Tempol
Tempol will be given as an adjunct to chemotherapy.

Locations
Country	Name	City	State
United States	UCHealth University of Colorado Cancer Center - Anschutz Medical Campus	Aurora	Colorado

Sponsors *(1)*
Lead Sponsor	Collaborator
Matrix Biomed, Inc.

Country where clinical trial is conducted

United States,

References & Publications (1)

Ravizza R, Cereda E, Monti E, Gariboldi MB. The piperidine nitroxide Tempol potentiates the cytotoxic effects of temozolomide in human glioblastoma cells. Int J Oncol. 2004 Dec;25(6):1817-22. — View Citation

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05094804` - A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents	Phase 1/Phase 2
Enrolling by invitation	`NCT00068003` - Harvesting Cells for Experimental Cancer Treatments
Recruiting	`NCT05798611` - Study of ART0380 in Patients With Biologically Selected Solid Tumors	Phase 2
Not yet recruiting	`NCT04931420` - Study Comparing Standard of Care Chemotherapy With/ Without Sequential Cytoreductive Surgery for Patients With Metastatic Foregut Cancer and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid Levels	Phase 2
Recruiting	`NCT05566574` - A Study of RP-3500 in Combination With Standard Radiation Therapy in People With Solid Tumor Cancer	Phase 1/Phase 2
Recruiting	`NCT05036681` - A Phase II Study of Futibatinib and Pembrolizumab in Metastatic Microsatellite Stable Endometrial Carcinoma	Phase 2
Withdrawn	`NCT00005030` - SCH 66336 Before Surgery in Treating Patients With Colorectal Cancer That Has Metastasized to the Liver	Phase 1
Recruiting	`NCT05525858` - KPMNG Study of MOlecular Profiling Guided Therapy Based on Genomic Alterations in Advanced Solid Tumors II
Recruiting	`NCT04085029` - Role of Ablative Radiotherapy in the Management of Metastatic Disease: A Patient Data Registry
Recruiting	`NCT06058988` - Trastuzumab Deruxtecan (T-DXd) for People With Brain Cancer	Phase 2
Not yet recruiting	`NCT05981170` - Rurality Adapted Physical Activity Sport Health
Not yet recruiting	`NCT03058809` - Evaluation of Viatar™ Oncopheresis System in Removing CTC From Whole Blood	Phase 1/Phase 2
Completed	`NCT02529553` - A Study of LY3076226 in Participants With Advanced or Metastatic Cancer	Phase 1
Terminated	`NCT01929941` - An Open-Label Study of a Novel JAK-inhibitor, INCB047986, Given in Patients With Advanced Malignancies	Phase 1
Terminated	`NCT00918645` - Calcium-41 (41Ca) Chloride Aqueous Solution in Diagnosing Patients With Prostate Cancer and Bone Metastasis	N/A
Completed	`NCT01302808` - Romidepsin and Erlotinib Hydrochloride in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer	Phase 1
Completed	`NCT00795678` - Chemotherapeutic Agents in Brain/Breast	N/A
Withdrawn	`NCT00769990` - Genistein in Treating Patients Undergoing External-Beam Radiation Therapy for Bone Metastases	Phase 1/Phase 2
Completed	`NCT00557102` - Cetuximab and Combination Chemotherapy as First-Line Therapy in Treating Patients With Colorectal Cancer That Has Spread to the Liver and/or Lung	Phase 2
Recruiting	`NCT00398437` - Magnetic Resonance Imaging for the Early Detection of CNS Metastases in Women With Stage IV Breast Cancer	N/A

Treatment of Metastatic Cancer in Terminally Diagnosed Patients

Clinical Trial Details — Status: Available

Administrative data

Study information